But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results